Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
Clinical trial NCT05540275 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05540275
- Sponsor
- Henan Provincial People's Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-05
- Primary completion
- 2024-12-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.